Pain and emotional distress among substance-Use patients beginning treatment relative to a representative comparison group

Katharina L. Wiest, Jason B. Colditz, Kathryn Carr, Victoria J. Asphaug, Dennis McCarty, Paul A. Pilkonis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: A secondary analysis assessed health-related quality-oflife (HRQOL) characteristics (ie, anxiety, depression, fatigue, and types of pain) among patients entering substance-use treatment and identified characteristics specific to treatment modalities relative to a representative comparison group.Methods: As part of a larger alcohol bank assessment, substance-use patients (n = 406) beginning methadone treatment (n = 170) or other outpatient treatment (n=236) and a comparison group representative of the general population (n = 1000) completed a survey measuring anxiety, depression, fatigue, pain interference, and pain in the last 7 days. Previous studies lacked comparable and concurrent assessments across these 3 groups.Results: Patients entering substance-use treatment had relatively high levels of emotional distress and poorer HRQOL relative to the general population. Among treatment modalities, patients beginning methadone treatment reported the highest levels of pain interference and pain behavior and the poorest physical functioning. Before the potentially modifying effects ofmethadone maintenance, patients beginning agonist therapy reported the greatest levels of compromised quality of life.Conclusions: These data present the magnitude of differences in HRQOL characteristics between treatment and comparison groups using the same assessment rubric and may help inform the design and timing of treatment modalities, thereby enhancing treatment efficacy for patients.

Original languageEnglish (US)
Pages (from-to)407-414
Number of pages8
JournalJournal of Addiction Medicine
Volume8
Issue number6
DOIs
StatePublished - Nov 1 2014

Fingerprint

Pain
Therapeutics
Methadone
Fatigue
Health
Anxiety
Depression
Population
Outpatients
Maintenance
Alcohols
Quality of Life

Keywords

  • Comparison group
  • Methadone
  • Pain
  • PROMIS
  • Substance use

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Pain and emotional distress among substance-Use patients beginning treatment relative to a representative comparison group. / Wiest, Katharina L.; Colditz, Jason B.; Carr, Kathryn; Asphaug, Victoria J.; McCarty, Dennis; Pilkonis, Paul A.

In: Journal of Addiction Medicine, Vol. 8, No. 6, 01.11.2014, p. 407-414.

Research output: Contribution to journalArticle

Wiest, Katharina L. ; Colditz, Jason B. ; Carr, Kathryn ; Asphaug, Victoria J. ; McCarty, Dennis ; Pilkonis, Paul A. / Pain and emotional distress among substance-Use patients beginning treatment relative to a representative comparison group. In: Journal of Addiction Medicine. 2014 ; Vol. 8, No. 6. pp. 407-414.
@article{7bd053f39c234a0db3aa99888b65db13,
title = "Pain and emotional distress among substance-Use patients beginning treatment relative to a representative comparison group",
abstract = "Objectives: A secondary analysis assessed health-related quality-oflife (HRQOL) characteristics (ie, anxiety, depression, fatigue, and types of pain) among patients entering substance-use treatment and identified characteristics specific to treatment modalities relative to a representative comparison group.Methods: As part of a larger alcohol bank assessment, substance-use patients (n = 406) beginning methadone treatment (n = 170) or other outpatient treatment (n=236) and a comparison group representative of the general population (n = 1000) completed a survey measuring anxiety, depression, fatigue, pain interference, and pain in the last 7 days. Previous studies lacked comparable and concurrent assessments across these 3 groups.Results: Patients entering substance-use treatment had relatively high levels of emotional distress and poorer HRQOL relative to the general population. Among treatment modalities, patients beginning methadone treatment reported the highest levels of pain interference and pain behavior and the poorest physical functioning. Before the potentially modifying effects ofmethadone maintenance, patients beginning agonist therapy reported the greatest levels of compromised quality of life.Conclusions: These data present the magnitude of differences in HRQOL characteristics between treatment and comparison groups using the same assessment rubric and may help inform the design and timing of treatment modalities, thereby enhancing treatment efficacy for patients.",
keywords = "Comparison group, Methadone, Pain, PROMIS, Substance use",
author = "Wiest, {Katharina L.} and Colditz, {Jason B.} and Kathryn Carr and Asphaug, {Victoria J.} and Dennis McCarty and Pilkonis, {Paul A.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1097/ADM.0000000000000072",
language = "English (US)",
volume = "8",
pages = "407--414",
journal = "Journal of Addiction Medicine",
issn = "1932-0620",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Pain and emotional distress among substance-Use patients beginning treatment relative to a representative comparison group

AU - Wiest, Katharina L.

AU - Colditz, Jason B.

AU - Carr, Kathryn

AU - Asphaug, Victoria J.

AU - McCarty, Dennis

AU - Pilkonis, Paul A.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Objectives: A secondary analysis assessed health-related quality-oflife (HRQOL) characteristics (ie, anxiety, depression, fatigue, and types of pain) among patients entering substance-use treatment and identified characteristics specific to treatment modalities relative to a representative comparison group.Methods: As part of a larger alcohol bank assessment, substance-use patients (n = 406) beginning methadone treatment (n = 170) or other outpatient treatment (n=236) and a comparison group representative of the general population (n = 1000) completed a survey measuring anxiety, depression, fatigue, pain interference, and pain in the last 7 days. Previous studies lacked comparable and concurrent assessments across these 3 groups.Results: Patients entering substance-use treatment had relatively high levels of emotional distress and poorer HRQOL relative to the general population. Among treatment modalities, patients beginning methadone treatment reported the highest levels of pain interference and pain behavior and the poorest physical functioning. Before the potentially modifying effects ofmethadone maintenance, patients beginning agonist therapy reported the greatest levels of compromised quality of life.Conclusions: These data present the magnitude of differences in HRQOL characteristics between treatment and comparison groups using the same assessment rubric and may help inform the design and timing of treatment modalities, thereby enhancing treatment efficacy for patients.

AB - Objectives: A secondary analysis assessed health-related quality-oflife (HRQOL) characteristics (ie, anxiety, depression, fatigue, and types of pain) among patients entering substance-use treatment and identified characteristics specific to treatment modalities relative to a representative comparison group.Methods: As part of a larger alcohol bank assessment, substance-use patients (n = 406) beginning methadone treatment (n = 170) or other outpatient treatment (n=236) and a comparison group representative of the general population (n = 1000) completed a survey measuring anxiety, depression, fatigue, pain interference, and pain in the last 7 days. Previous studies lacked comparable and concurrent assessments across these 3 groups.Results: Patients entering substance-use treatment had relatively high levels of emotional distress and poorer HRQOL relative to the general population. Among treatment modalities, patients beginning methadone treatment reported the highest levels of pain interference and pain behavior and the poorest physical functioning. Before the potentially modifying effects ofmethadone maintenance, patients beginning agonist therapy reported the greatest levels of compromised quality of life.Conclusions: These data present the magnitude of differences in HRQOL characteristics between treatment and comparison groups using the same assessment rubric and may help inform the design and timing of treatment modalities, thereby enhancing treatment efficacy for patients.

KW - Comparison group

KW - Methadone

KW - Pain

KW - PROMIS

KW - Substance use

UR - http://www.scopus.com/inward/record.url?scp=84921955867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921955867&partnerID=8YFLogxK

U2 - 10.1097/ADM.0000000000000072

DO - 10.1097/ADM.0000000000000072

M3 - Article

C2 - 25275876

AN - SCOPUS:84921955867

VL - 8

SP - 407

EP - 414

JO - Journal of Addiction Medicine

JF - Journal of Addiction Medicine

SN - 1932-0620

IS - 6

ER -